Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) EBITDA (2023 - 2025)

Historic EBITDA for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$16.8 million.

  • Applied Therapeutics' EBITDA rose 4365.73% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.4 million, marking a year-over-year decrease of 663.06%. This contributed to the annual value of -$104.3 million for FY2024, which is 6161.62% down from last year.
  • Applied Therapeutics' EBITDA amounted to -$16.8 million in Q3 2025, which was up 4365.73% from -$23.1 million recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' EBITDA registered a high of -$10.9 million during Q1 2023, and its lowest value of -$33.0 million during Q4 2024.
  • For the 3-year period, Applied Therapeutics' EBITDA averaged around -$21.3 million, with its median value being -$21.0 million (2023).
  • In the last 5 years, Applied Therapeutics' EBITDA plummeted by 9426.23% in 2024 and then soared by 4365.73% in 2025.
  • Quarter analysis of 3 years shows Applied Therapeutics' EBITDA stood at -$21.0 million in 2023, then crashed by 57.19% to -$33.0 million in 2024, then skyrocketed by 49.25% to -$16.8 million in 2025.
  • Its EBITDA stands at -$16.8 million for Q3 2025, versus -$23.1 million for Q2 2025 and -$25.5 million for Q1 2025.